Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.74 |
| ▸ | POLB | P06746 | 4/20 | 0.74 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.60 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.60 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.60 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.59 |
| ▸ | RAB9A | P51151 | 4/20 | 0.57 |
| ▸ | NPC1 | O15118 | 3/20 | 0.57 |
| ▸ | MEN1 | O00255 | 3/20 | 0.57 |
| ▸ | GFER | P55789 | 1/20 | 0.57 |
| ▸ | GAA | P10253 | 5/20 | 0.56 |
| ▸ | HTT | P42858 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | HPGD | P15428 | 3/20 | 0.53 |
| ▸ | USP2 | O75604 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.52 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15747145 | 0.86 | KMT2A (0.57) | KMT2APOLBCYP1A2CYP2D6CYP2C9 | |
| SCHEMBL15996247 | 0.86 | KMT2A (0.57) | KMT2APOLBCYP1A2CYP2D6CYP2C9 | |
| SCHEMBL6757227 | 0.86 | KMT2A (0.81) | KMT2APOLBCYP1A2CYP2D6CYP2C9 | |
| SCHEMBL10038839 | 0.85 | DDAH1 (0.59) | KMT2APOLBCYP1A2CYP2D6CYP2C9 | |
| SCHEMBL15947556 | 0.84 | KMT2A (0.72) | KMT2APOLBCYP1A2CYP2D6CYP2C9 | |
| SCHEMBL18765332 | 0.84 | KMT2A (0.72) | KMT2APOLBCYP1A2CYP2D6CYP2C9 | |
| SCHEMBL9720980 | 0.83 | KMT2A (0.84) | KMT2APOLBCYP1A2CYP2D6CYP2C9 | |
| Hydrochloric Acid SCHEMBL28836137 | 0.82 | KMT2A (0.75) | KMT2APOLBCYP1A2CYP2D6CYP2C9 | |
| SCHEMBL9721050 | 0.82 | KMT2A (0.82) | KMT2APOLBCYP1A2CYP2D6CYP2C9 | |
| SCHEMBL868184 | 0.81 | DDAH1 (0.59) | KMT2APOLBCYP1A2CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230355609-A1 | Spirolactone Compounds | QUIXGEN, INC. (US) | 2023-11-09 | — | — | US | disclosed |
| US-20230355609-A1 | Spirolactone Compounds | QUIXGEN, INC. (US) | 2023-11-09 | — | — | US | disclosed |
| WO-2019006324-A1 | NOVEL SPIROLACTONE COMPOUNDS | QUIXGEN, INC. (US) | 2019-01-03 | — | — | WO | disclosed |
| CN-105503737-B | Method for preparing benzimidazole or benzothiazole compounds without catalyst | 大连理工大学 | 2018-06-19 | — | — | CN | disclosed |
| US-9802949-B2 | Fused ring compounds as hepatitis C virus inhibitors, pharmaceutical compositions and uses thereof | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2017-10-31 | — | — | US | disclosed |
| US-20170190717-A1 | Compounds and Methods for Inhibition of Hedgehog Signaling and Phosphodiesterase | VANDERBILT UNIVERSITY | 2017-07-06 | — | — | US | disclosed |
| US-9586978-B2 | Anti-viral compounds | ABBVIE INC. (US) | 2017-03-07 | — | — | US | disclosed |
| US-20170029408-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2017-02-02 | — | — | US | disclosed |
| US-9511056-B2 | Antiviral compounds | GILEAD PHARMASSET LLC (US) | 2016-12-06 | — | — | US | disclosed |
| US-9416139-B2 | Spiro ring compound as hepatitis C virus (HCV) inhibitor and uses thereof | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2016-08-16 | — | — | US | disclosed |
| US-20120172290-A1 | Anti-Viral Compounds | ABBOTT LABORATORIES (US) | 2012-07-05 | — | — | US | disclosed |
| US-20120142625-A1 | Substituted Purine And 7-Deazapurine Compounds | Epizyme, Inc. (US) | 2012-06-07 | — | — | US | disclosed |
| US-20120039848-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2012-02-16 | — | — | US | disclosed |
| US-20110142798-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2011-06-16 | — | — | US | disclosed |
| US-20110092415-A1 | Anti-Viral Compounds | Abbott Labaoratories (US) | 2011-04-21 | — | — | US | disclosed |
| US-20100305118-A1 | PYRIMIDINE INHIBITORS OF KINASE ACTIVITY | ABBOTT LABORATORIES (US) | 2010-12-02 | — | — | US | disclosed |
| US-20100267634-A1 | Anti-Viral Compounds | Abbott Labaoratories (US) | 2010-10-21 | — | — | US | disclosed |
| US-20100260715-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2010-10-14 | — | — | US | disclosed |
| US-7312229-B2 | 21-Heterocyclic-4-azasteroid derivatives as androgen receptor modulators | MERCK & CO., INC. (US) | 2007-12-25 | — | — | US | disclosed |
| US-20070088047-A1 | 21-Heterocyclic-4-azasteroid derivatives as androgen receptor modulators | MERCK SHARP & DOHME CORP. | 2007-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267634-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | KMT2A 4093/4885POLB 138/4885CYP1A2 2958/4885 |
| US-20170029408-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | KMT2A 3803/4885POLB 57/4885CYP1A2 3826/4885 |
| US-20120039848-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, SLC10A1, EIF2AK2 | KMT2A 2957/4885POLB 682/4885CYP1A2 205/4885 |
| US-20100260715-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, SLC10A1, EIF2AK2 | KMT2A 2957/4885POLB 682/4885CYP1A2 205/4885 |
| US-20070088047-A1 | 21-Heterocyclic-4-azasteroid derivatives as androgen receptor modulators | NR5A1, AR, NR3C1 | KMT2A 1438/4885POLB 2104/4885CYP1A2 654/4885 |
| US-20100305118-A1 | PYRIMIDINE INHIBITORS OF KINASE ACTIVITY | IGF1R, TK1, CDK2 | KMT2A 2972/4885POLB 277/4885CYP1A2 2413/4885 |
| US-20110092415-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | KMT2A 4093/4885POLB 138/4885CYP1A2 2958/4885 |
| US-20110142798-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, SLC10A1, EIF2AK2 | KMT2A 2957/4885POLB 682/4885CYP1A2 205/4885 |
| US-20170190717-A1 | Compounds and Methods for Inhibition of Hedgehog Signaling and Phosphodiesterase | PDE4A, PDE4B, PDE7A | KMT2A 3118/4885POLB 2192/4885CYP1A2 3725/4885 |
| US-20230355609-A1 | Spirolactone Compounds | ACACA, AKR1C2, AKR1A1 | KMT2A 3481/4885POLB 2141/4885CYP1A2 204/4885 |
| US-20120142625-A1 | Substituted Purine And 7-Deazapurine Compounds | TPMT, DIMT1, DAZAP1 | KMT2A 177/4885POLB 1016/4885CYP1A2 2702/4885 |
| US-20120172290-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | KMT2A 4093/4885POLB 138/4885CYP1A2 2958/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.